These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 19064381

  • 21. Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
    Bennett CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ.
    Semin Thromb Hemost; 2007 Jun; 33(4):365-72. PubMed ID: 17525894
    [Abstract] [Full Text] [Related]

  • 22. Consumer groups look to improve adverse event reporting systems.
    Vastag B.
    J Natl Cancer Inst; 2005 Dec 21; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct 30; 65(210):64607-19. PubMed ID: 11503687
    [Abstract] [Full Text] [Related]

  • 25. A proposal for a national program reporting beneficial drug responses, analogous to the existing program to detect adverse drug responses.
    Bond RA.
    Med Hypotheses; 2006 Oct 30; 66(1):10-3. PubMed ID: 16198061
    [Abstract] [Full Text] [Related]

  • 26. US lawmakers tackle safety reforms at the FDA.
    Zwillich T.
    Lancet; 2007 Jun 16; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
    Seruga B, Sterling L, Wang L, Tannock IF.
    J Clin Oncol; 2011 Jan 10; 29(2):174-85. PubMed ID: 21135271
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS, Mello MM.
    Health Aff (Millwood); 2007 Jan 10; 26(2):483-91. PubMed ID: 17339677
    [Abstract] [Full Text] [Related]

  • 32. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2007 Oct 18; 72(201):58993-9000. PubMed ID: 17966558
    [Abstract] [Full Text] [Related]

  • 33. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J.
    Mod Healthc; 2007 Oct 08; 37(40):16. PubMed ID: 18018373
    [No Abstract] [Full Text] [Related]

  • 34. Adverse drug effects: new information about an old problem.
    Miller CA.
    Geriatr Nurs; 2001 Oct 08; 22(6):336-7. PubMed ID: 11780009
    [No Abstract] [Full Text] [Related]

  • 35. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2009 Jul 28; 74(143):37163-8. PubMed ID: 19655468
    [Abstract] [Full Text] [Related]

  • 36. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan 28; 71(1):34-9. PubMed ID: 16491527
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist.
    O'Malley P.
    Clin Nurse Spec; 2007 Jan 28; 21(4):188-90. PubMed ID: 17622806
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.